Dossier bibliographique d’information sur la
Neto MG, Moon RC, de Quadros LG, Grecco E, Filho AC, de Souza TF, Mattar LA, de Sousa JAG, Dayyeh BKA, Morais H, Matz F,
Jawad MA, Teixeira AF.
Surg Endosc. 2019 Oct
Endoscopic sleeve gastroplasty (ESG) is an option for patients with Class I and II obesity or patients who refuse to undergo a
laparoscopic bariatric surgery. The aims of this study are as follows: (1) to demonstrate a short-term outcome after primary ESG
and (2) to compare the effectiveness of weight loss between Class I and Class II obesity patients.
Patients undergoing ESG at four bariatric centers in Brazil between April 1, 2017 and December 31, 2018 were prospectively
enrolled in the study (BMI 30.0-39.9 kg/m2). ESG was performed using Overstitch (Apollo Endosurgery, Austin, TX).
Descriptive analysis, t test, Chi-square test, and Mann-Whitney test were used to present the results.
A total of 233 patients underwent primary ESG. The mean age and BMI of the patients were 41.1 years and 34.7 kg/m2,
respectively. Following ESG, the mean percentage of total weight loss (TWL) was 17.1% at 6 months and 19.7% at 12 months.
Percentage of excess BMI loss (EBMIL) was 47.3% at 6 months and 54.8% at 12 months after ESG. The mean EBMIL was
significantly greater among patients with Class I obesity than those with Class II obesity at 6 (51.1% vs. 43.7%) and 12 months
(60.2% vs. 49.2%). One patient experienced bleeding during the procedure that was managed with sclerotherapy.
Short-term results suggest that ESG is a safe and effective option for patients with Class I and II obesity.